ADMA Biologics (NASDAQ:ADMA) Upgraded by BidaskClub to Sell

ADMA Biologics (NASDAQ:ADMA) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Tuesday, BidAskClub reports.

A number of other brokerages also recently weighed in on ADMA. Maxim Group set a $12.00 price objective on ADMA Biologics and gave the company a “buy” rating in a research note on Monday, October 21st. ValuEngine downgraded ADMA Biologics from a “hold” rating to a “sell” rating in a research note on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating on shares of ADMA Biologics in a research note on Wednesday, January 8th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $10.20.

Shares of ADMA traded up $0.14 during midday trading on Tuesday, reaching $4.54. 14,627 shares of the stock were exchanged, compared to its average volume of 801,419. The firm has a 50 day simple moving average of $4.19 and a 200-day simple moving average of $4.25. The company has a quick ratio of 3.76, a current ratio of 6.42 and a debt-to-equity ratio of 2.33. ADMA Biologics has a 12-month low of $2.56 and a 12-month high of $6.31. The company has a market cap of $266.94 million, a price-to-earnings ratio of -3.11 and a beta of 2.58.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.04. ADMA Biologics had a negative return on equity of 203.21% and a negative net margin of 260.92%. The business had revenue of $7.22 million for the quarter, compared to the consensus estimate of $5.71 million. Research analysts expect that ADMA Biologics will post -0.94 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ADMA. Charles Schwab Investment Management Inc. grew its holdings in ADMA Biologics by 49.2% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 65,180 shares of the biotechnology company’s stock valued at $253,000 after buying an additional 21,480 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in ADMA Biologics by 35.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 82,176 shares of the biotechnology company’s stock valued at $317,000 after buying an additional 21,545 shares during the last quarter. Northern Trust Corp grew its holdings in ADMA Biologics by 14.4% in the 2nd quarter. Northern Trust Corp now owns 299,248 shares of the biotechnology company’s stock valued at $1,158,000 after buying an additional 37,677 shares during the last quarter. Parametric Portfolio Associates LLC acquired a new stake in ADMA Biologics in the 2nd quarter valued at approximately $49,000. Finally, BlackRock Inc. grew its holdings in ADMA Biologics by 94.0% in the 2nd quarter. BlackRock Inc. now owns 1,897,484 shares of the biotechnology company’s stock valued at $7,343,000 after buying an additional 919,260 shares during the last quarter. 62.70% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Read More: What is the Dividend Aristocrat Index?

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.